2. Signaling Pathways
  3. GPCR/G Protein
  4. Leukotriene Receptor

Leukotriene Receptor

Leukotriene Receptor

Related Products

PDF 0.82 MB

Leukotriene Receptor (cys-LTs) are a family of potent bioactive lipids that act through two structurally divergent G protein-coupled receptors, termed the CysLT1 and CysLT2 receptors. The cysteinyl leukotrienes LTC4, LTD4, and LTE4 are important mediators of human bronchial asthma. Leukotriene Receptor is a member of the superfamily of G protein-coupled receptors and uses a phosphatidylinositol-calcium second messenger system. Activation of CysLT1 by LTD4 results in contraction and proliferation of smooth muscle, oedema, eosinophil migration and damage to the mucus layer in the lung. Leukotriene receptor antagonists, called LTRAs for short, are a class of oral medication that is non-steroidal. They may also be referred to as anti-inflammatory bronchoconstriction preventors. LTRAs work by blocking a chemical reaction that can lead to inflammation in the airways.

Leukotriene Receptor Isoform Specific Products:

Leukotriene Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-113693
    ONO-RS-347
    		Antagonist
    ONO-RS-347 is an orally active and potent antagonist of leukotriene C4 and D4. ONO-RS-347 inhibits LTD4-induced bronchoconstriction in guinea pigs. ONO-RS-347 is promising for research of allergic asthma and other immediate hypersensitivty diseases.
    ONO-RS-347
  • HY-149084
    LTB4 antagonist 3
    		Antagonist
    LTB4 antagonist 3 (compound 24e) is a leukotriene B4 (LTB4) antagonist with an IC50 value of 477 nM. LTB4 antagonist 3 has anti-inflammatory activity.
    LTB4 antagonist 3
  • HY-130138B
    (5S,6R)-DiHETEs
    		Control
    (5S,6R)-DiHETEs is the isomer of (5S,6R)-DiHETE (HY-130138A). (5S,6R)-DiHETE can be recognized by leukotriene receptors (LTD4 receptors). (5S,6R)-DiHETE can induce guinea pig isolated ileum contraction with an EC50 of 1.3 μM, and this effect can be inhibited by LTD4 receptor antagonists.
    (5S,6R)-DiHETEs
  • HY-155204
    LTB4-IN-2
    		Inhibitor
    LTB4-IN-2 (Comopund 6x) is a Leukotriene B4 (LTB4) inhibitor. LTB4-IN-2 inhibits Leukotriene B4 formation (IC50: 1.15 μM) by selectively targeting 5-Lipoxygenase-activating protein (FLAP). LTB4-IN-2 can be used for anti-inflammatory research.
    LTB4-IN-2
  • HY-100724
    YM-17690
    		Agonist
    YM-17690 is a LTD4 and LTE4 agonist, with a pKi value of 9.28 for [3H]LTD4. It induces dose-dependent contractions in guinea pig ileum, lung parenchyma, and trachea, with EC50 values of 16, 3.9, and 22 nM, respectively. YM-17690 can be used in research related to asthma and inflammation.
    YM-17690
  • HY-19020
    FK-664
    		Inhibitor
    FK-664 is a leukotriene inhibitor. FK-664 enhances ventricular contractility and shortens the time to peak tension in cardiac cells. FK-664 reduces mean circulating pressure (MCP) in a canine model of heart failure. FK-664 can be used in research on cardiovascular diseases such as heart failure.
    FK-664
  • HY-112736
    RG 14893
    		Antagonist
    RG 14893 is a high affinity, competitive, orally active leukotriene B4 receptor antagonist.
    RG 14893
  • HY-118958
    Ablukast
    		Antagonist 99.36%
    Ablukast (Ro 23-3544) is a specific and active leukotriene receptor antagonist. Ablukast effectively reduces LTC4- and antigen-induced bronchoconstriction. Ablukast is LTD4 receptor antagonist.
    Ablukast
  • HY-19161
    Bay-X-7195
    		Antagonist
    Bay-X-7195 is a CYS leukotriene 1 receptor (CYS LT1) antagonist. Bay-X-7195 shows an antagonistic action to LTD4-induced bronchoconstriction in vitro and in vivo. Bay-X-7195 can be used foe the study of allergic and asthmatic.
    Bay-X-7195
  • HY-180411
    SM-15178
    		Antagonist
    SM-15178 is a potent, orally active and selective leukotriene B4 (LTB4) receptor antagonist with an IC50 of 0.30 μM. SM-15178 attenuates LTB4 (HY-107608)-induced neutrophil accumulation in mouse skin and bronchoconstriction in guinea pigs. SM-15178 emonstrates significant anti-inflammatory efficacy across multiple animal models of inflammation. SM-15178 can be used for the research of chronic inflammatory diseases such as inflammatory bowel disease, psoriasis, and asthma.
    SM-15178
  • HY-112740
    SC-53228
    		Antagonist
    SC-53228 is an orally active human leukotriene B4 receptor (LTB4 receptor) antagonist. SC-53228 exerts its anti-inflammatory effect by specifically blocking the LTB4 receptor and inhibiting neutrophil infiltration. SC-53228 has demonstrated significant efficacy and good safety in various inflammatory models. SC-53228 can be used for a variety of inflammatory diseases, such as psoriasis and ulcerative colitis.
    SC-53228
  • HY-B0290S1
    Pranlukast-d4
    		Antagonist
    Pranlukast-d4 is deuterium labeled Pranlukast. Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.
    Pranlukast-d<sub>4</sub>
  • HY-118979
    L-691678
    		Inhibitor
    L-691678 can bind to FLAP by recognizing the amino acid residues of 5-lipoxygenase-activating protein (FLAP), thereby inhibiting leukotriene biosynthesis. L-691678 can be used in the study of leukotriene-related diseases such as allergies, asthma, and inflammation.
    L-691678
  • HY-117854
    SB 201146
    		Antagonist
    SB 201146 is an LTB4 receptor antagonist with a potency range of 10 pM to 1 μM that plays a critical role in asthma-associated airway inflammation. Studies have focused on its effects on eosinophil survival, a hallmark of asthma pathology. Studies have shown that eosinophil-derived cysteinyl leukotrienes, including LTC4 and LTD4, as well as factors such as GM-CSF and fibronectin promote eosinophil survival. SB 201146 effectively reversed mast cell- and lymphocyte-induced eosinophil survival, highlighting its potential therapeutic role in disrupting the autocrine cysteinyl leukotriene pathway that maintains eosinophil viability. This antagonist also highlights the importance of LTB4 as a paracrine mediator that influences eosinophil survival in inflammatory settings such as asthma.
    SB 201146
  • HY-106929R
    Moxilubant (Standard)
    		Antagonist
    Moxilubant (CGS 25019C free base) Standard is the analytical standard of Moxilubant (HY-106929). This product is intended for research and analytical applications. Moxilubant (CGS 25019C free base) is an orally active BLT1 antagonist. Moxilubant inhibits LTB4 signaling with a potency of 2-4 nM. Moxilubant blocks LTB4-induced neutrophil functions. Moxilubant inhibits ear edema and neutrophil infiltration in mice. Moxilubant can be used in research related to chronic obstructive pulmonary disease.
    Moxilubant (Standard)
  • HY-127113
    Q8
    		Antagonist
    Q8, an effective antiangiogenic drug, is a CysLt1 antagonist (IC50 of 4.9 μM). Q8 is sufficient to reduce cellular levels of NF-κB and calpain-2 and secreted levels of the proangiogenic proteins intercellular adhesion molecule-1, vascular cell adhesion protein-1, and VEGF.
    Q8
  • HY-120486
    LY203647
    		Antagonist
    LY203647 is an orally active antagonist for leukotriene receptor LTD4 and LTE4. LY203647 can be used in research about asthma and other inflammation diseases.
    LY203647
  • HY-19109
    RG-7152
    		Antagonist
    RG-7152 is a tetrazolyl-substituted leukotriene D4 receptor antagonist that can induce peroxisomal β-oxidation and peroxisome bifunctional enzymes (PBEs) in hepatocytes in various animal models. It has been shown to significantly increase PBE levels and β-oxidation activity in rat and mouse liver homogenates, while smaller effects were observed in guinea pigs and monkeys and no effect in dogs. In vitro studies have also shown that it can induce PBEs comparable to clofibric acid, indicating its potential as a peroxisome proliferator.
    RG-7152
  • HY-13448R
    Nedocromil (Standard)
    		Inhibitor
    Nedocromil (Standard) is the analytical standard of Nedocromil. This product is intended for research and analytical applications. Nedocromil suppresses the action or formation of multiple mediators, including histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2).
    Nedocromil (Standard)
  • HY-17492S
    Zafirlukast-d7
    		Antagonist
    Zafirlukast-d7 is the deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.
    Zafirlukast-d<sub>7</sub>
Cat. No. Product Name / Synonyms Application Reactivity
Leukotriene Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.